All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation
During the EHA2021 Virtual Congress, the Multiple Myeloma Hub spoke with Maria-Victoria Mateos, University Hospital of Salamanca, Salamanca, ES. We asked, What are the major advances for the triple-class exposed population?
What are the major advances for the triple-class exposed population?
In this video, Mateos discusses the major advances in treatment for triple-class exposed patients with multiple myeloma, including melflufen, selinexor, and B-cell maturation antigen chimeric antigen receptor T-cell therapy.
How to treat triple-class refractory MM?
Interview with Shaji Kumar, Mayo Clinic, US, about how to treat patients with triple-class refractory MM.
ASH 2020| Practice-changing and breakthrough abstracts in multiple myeloma
The Multiple Myeloma Hub attended the virtual 62nd ASH Annual Meeting & Exposition, December, 5–8 2020, and has developed two downloadable resources, which provides...
Subscribe to get the best content related to multiple myeloma delivered to your inbox